GU81, a VEGFR2 antagonist peptoid, enhances the anti-tumor activity of doxorubicin in the murine MMTV-PyMT transgenic model of breast cancer

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Lynn, Kristi D ^a,b   Udugamasooriya, D Gomika ^a,b   Roland, Christina L ^a   Castrillon, Diego H ^a   Kodadek, Thomas J ^a,c   Brekken, Rolf A ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; DOXORUBICIN; GU 40C4; GU 81; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 2; ANTINEOPLASTIC AGENT; GU 81 COMPOUND; PEPTIDE; PEPTOID; VASCULOTROPIN A;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL INFILTRATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG STRUCTURE; FAT CONTENT; HISTOLOGY; IN VITRO STUDY; IN VIVO STUDY; MICROENVIRONMENT; MONOTHERAPY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; ANIMAL; DRUG ANTAGONISM; DRUG COMBINATION; DRUG SCREENING; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL NEOPLASM; FEMALE; GENETICS; HUMAN; MACROPHAGE; METABOLISM; MOUSE MAMMARY TUMOR ONCOVIRUS; PATHOLOGY; TRANSGENIC MOUSE; TUMOR CELL CULTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; DOXORUBICIN; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MACROPHAGES; MAMMARY NEOPLASMS, EXPERIMENTAL; MAMMARY TUMOR VIRUS, MOUSE; MICE; MICE, TRANSGENIC; PEPTIDES; PEPTOIDS; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77955082181     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-397     Document Type: Article

References (35)

1. American Cancer Society: Cancer Facts and Figures 2009. Atlanta, GA: American Cancer Society 2009,
2. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285(21):1182-1186. 10.1056/NEJM197111182852108, 4938153.
3. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002, 29(6 Suppl 16):15-18.
4. Folkman J. Angiogenesis: an organizing principle for drug discovery?. Nat Rev Drug Discov 2007, 6(4):273-286. 10.1038/nrd2115, 17396134.
5. Pradeep CR, Sunila ES, Kuttan G. Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies. Integr Cancer Ther 2005, 4(4):315-321. 10.1177/1534735405282557, 16282508.
6. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350(23):2335-2342. 10.1056/NEJMoa032691, 15175435.
7. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007, 357(26):2666-2676. 10.1056/NEJMoa072113, 18160686.
8. Lacouture ME, Reilly LM, Gerami P, Guitart J. Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol 2008, 19(11):1955-1961. 10.1093/annonc/mdn389, 18550575.
9. Roland CL, Dineen SP, Lynn KD, Sullivan LA, Dellinger MT, Sadegh L, Sullivan JP, Shames DS, Brekken RA. Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts. Mol Cancer Ther 2009, 8(7):1761-1771. 10.1158/1535-7163.MCT-09-0280, 19567820.
10. Roland CL, Lynn KD, Toombs JE, Dineen SP, Udugamasooriya DG, Brekken RA. Cytokine levels correlate with immune cell infiltration after anti-VEGF therapy in preclinical mouse models of breast cancer. PLoS One 2009, 4(11):e7669. 10.1371/journal.pone.0007669, 2766251, 19888452.
11. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008, 7(10):3129-3140. 10.1158/1535-7163.MCT-08-0013, 18852116.
12. Udugamasooriya DG, Dineen SP, Brekken RA, Kodadek T. A peptoid "antibody surrogate" that antagonizes VEGF receptor 2 activity. J Am Chem Soc 2008, 130(17):5744-5752. 10.1021/ja711193x, 18386897.
13. Simon RJ, Kania RS, Zuckermann RN, Huebner VD, Jewell DA, Banville S, Ng S, Wang L, Rosenberg S, Marlowe CK, et al. Peptoids: a modular approach to drug discovery. Proc Natl Acad Sci USA 1992, 89(20):9367-9371. 10.1073/pnas.89.20.9367, 50132, 1409642.
14. Lin EY, Jones JG, Li P, Zhu L, Whitney KD, Muller WJ, Pollard JW. Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol 2003, 163(5):2113-2126. 1892434, 14578209.
15. Udugamasooriya DG, Dunham G, Ritchie C, Brekken RA, Kodadek T. The pharmacophore of a peptoid VEGF receptor 2 antagonist includes both side chain and main chain residues. Bioorg Med Chem Lett 2008, 18(22):5892-5894. 10.1016/j.bmcl.2008.07.023, 2593102, 18653335.
16. Souza SC, de Vargas LM, Yamamoto MT, Lien P, Franciosa MD, Moss LG, Greenberg AS. Overexpression of perilipin A and B blocks the ability of tumor necrosis factor alpha to increase lipolysis in 3T3-L1 adipocytes. J Biol Chem 1998, 273(38):24665-24669. 10.1074/jbc.273.38.24665, 9733764.
17. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995, 270(45):26746-26749. 10.1074/jbc.270.45.26746, 7592907.
18. Greenberg AS, Egan JJ, Wek SA, Garty NB, Blanchette-Mackie EJ, Londos C. Perilipin, a major hormonally regulated adipocyte-specific phosphoprotein associated with the periphery of lipid storage droplets. J Biol Chem 1991, 266(17):11341-11346.
19. Diez JJ, Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol 2003, 148(3):293-300. 10.1530/eje.0.1480293, 12611609.
20. Ukkola O, Santaniemi M. Adiponectin: a link between excess adiposity and associated comorbidities?. J Mol Med 2002, 80(11):696-702. 10.1007/s00109-002-0378-7, 12436346.
21. Renaldi O, Pramono B, Sinorita H, Purnomo LB, Asdie RH, Asdie AH. Hypoadiponectinemia: a risk factor for metabolic syndrome. Acta Med Indones 2009, 41(1):20-24.
22. Borowsky AD, Namba R, Young LJ, Hunter KW, Hodgson JG, Tepper CG, McGoldrick ET, Muller WJ, Cardiff RD, Gregg JP. Syngeneic mouse mammary carcinoma cell lines: two closely related cell lines with divergent metastatic behavior. Clin Exp Metastasis 2005, 22(1):47-59. 10.1007/s10585-005-2908-5, 16132578.
23. Dineen SP, Lynn KD, Holloway SE, Miller AF, Sullivan JP, Shames DS, Beck AW, Barnett CC, Fleming JB, Brekken RA. Vascular endothelial growth factor receptor 2 mediates macrophage infiltration into orthotopic pancreatic tumors in mice. Cancer Res 2008, 68(11):4340-4346. 10.1158/0008-5472.CAN-07-6705, 18519694.
24. Lin EY, Nguyen AV, Russell RG, Pollard JW. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 2001, 193(6):727-740. 10.1084/jem.193.6.727, 2193412, 11257139.
25. Ferrara N. VEGF as a therapeutic target in cancer. Oncology 2005, 69(Suppl 3):11-16. 10.1159/000088479, 16301831.
26. Cobleigh MA, Langmuir VK, Sledge GW, Miller KD, Haney L, Novotny WF, Reimann JD, Vassel A. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003, 30(5 Suppl 16):117-124. 10.1053/j.seminoncol.2003.08.013, 14613032.
27. Liang WC, Wu X, Peale FV, Lee CV, Meng YG, Gutierrez J, Fu L, Malik AK, Gerber HP, Ferrara N, et al. Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J Biol Chem 2006, 281(2):951-961. 10.1074/jbc.M508199200, 16278208.
28. Brekken RA, Overholser JP, Stastny VA, Waltenberger J, Minna JD, Thorpe PE. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res 2000, 60(18):5117-5124.
29. Barr MP, Bouchier-Hayes DJ, Harmey JJ. Vascular endothelial growth factor is an autocrine survival factor for breast tumour cells under hypoxia. Int J Oncol 2008, 32(1):41-48.
30. Leek RD, Harris AL. Tumor-associated macrophages in breast cancer. J Mammary Gland Biol Neoplasia 2002, 7(2):177-189. 10.1023/A:1020304003704, 12463738.
31. Leek RD, Lewis CE, Whitehouse R, Greenall M, Clarke J, Harris AL. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res 1996, 56(20):4625-4629.
32. Salnikov AV, Heldin NE, Stuhr LB, Wiig H, Gerber H, Reed RK, Rubin K. Inhibition of carcinoma cell-derived VEGF reduces inflammatory characteristics in xenograft carcinoma. Int J Cancer 2006, 119(12):2795-2802. 10.1002/ijc.22217, 17019708.
33. Whitehurst B, Flister MJ, Bagaitkar J, Volk L, Bivens CM, Pickett B, Castro-Rivera E, Brekken RA, Gerard RD, Ran S. Anti-VEGF-A therapy reduces lymphatic vessel density and expression of VEGFR-3 in an orthotopic breast tumor model. Int J Cancer 2007, 121(10):2181-2191. 10.1002/ijc.22937, 17597103.
34. Astle JM, Udugamasooriya DG, Smallshaw JE, Kodadek T. A VEGFR2 Antagonist and Other Peptoids Evade Immune Recognition. International Journal of Peptide Research and Therapeutics 2008, 14:223-227.
35. Kwon YU, Kodadek T. Quantitative evaluation of the relative cell permeability of peptoids and peptides. J Am Chem Soc 2007, 129(6):1508-1509. 10.1021/ja0668623, 2530819, 17283989.